WAP
RARE icon

Wealthcare Advisory Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Wealthcare Advisory Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-337
Closed -$26K – 1290
2018
Q2 		$26K Buy
+337
New +$21.8K 0.01% 608

Other funds holding RARE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wealthcare Advisory Partners's RARE Position: Q3 2018 in Review

Wealthcare Advisory Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2018, closing a stake of 337 shares — an estimated $26K sold.

Wealthcare Advisory Partners first reported a position in RARE in Q2 2018 and held it in 1 quarter. The position peaked at $26K in Q2 2018. 176 funds tracked by Wall St. Rank hold RARE as of Q3 2018.

  • Wealthcare Advisory Partners reported no remaining Ultragenyx Pharmaceutical position as of Q3 2018 after selling out during the quarter.
  • Wealthcare Advisory Partners sold 337 Ultragenyx Pharmaceutical shares in Q3 2018, an estimated $26K.
  • Wealthcare Advisory Partners first reported a position in Ultragenyx Pharmaceutical in Q2 2018 and held it in 1 quarter.
  • Wealthcare Advisory Partners's Ultragenyx Pharmaceutical position peaked at $26K in Q2 2018.
  • 176 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2018.

Based on Wealthcare Advisory Partners's 13F filing for Q3 2018, filed 14 Nov 2018.